Conditions: Kidney Cancer
Keywords: kidney cancer bevacizumab
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 80
Healthy volunteers: no

Brief summary:
This phase II trial will evaluate the combination of bevacizumab + RAD001 in patients with metastatic renal cell carcinoma. In this trial the investigators will evaluate this combination in patients previously untreated with any anti-angiogenesis agent and patients who have previously received one prior regimen containing an anti-angiogenesis agent.

Detailed description:
All eligible patients will receive:

* Bevacizumab 10mg/kg, IV infusion, every 2 weeks
* RAD001 10 mg by mouth daily

All patients will be evaluated for response after completing two courses (8 weeks) of treatment. Patients with objective tumor response or stable disease will continue treatment with bevacizumab adn RAD001 on the same schedule. Treatment will continue until disease progression occurs.

Arms:
arm 1: Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily

Interventions: intervention 1: bevacizumab intervention 2: RAD001
Intervention descriptions: intervention 1: Bevacizumab 10mg/kg, IV infusion, every 2 weeks intervention 2: RAD001 10 mg by mouth daily

Protocol document: